XML 65 R23.htm IDEA: XBRL DOCUMENT v3.19.3
FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS (Tables)
9 Months Ended
Sep. 30, 2019
Fair Value Disclosures [Abstract]  
Summary of Carrying Amounts and Fair Values of Financial Instruments Measured
The following tables set forth the carrying amounts and fair values of the Company's financial instruments measured at fair value on a recurring basis as of September 30, 2019 and December 31, 2018 (in thousands):
 
September 30, 2019
 
 
 
 
 
Fair Value Measurement Based on
 
Carrying Amount
 
Fair Value
 
Quoted Prices in Active
Markets
(Level 1)
 
Significant other Observable
Inputs
(Level 2)
 
Significant Unobservable
Inputs
(Level 3)
Assets:
 
 
 
 
 
 
 
 
 
Money market funds
(cash equivalents)
$
30,995

 
$
30,995

 
$
30,995

 
$

 
$

Liabilities:
 
 
 
 
 
 
 
 
 
Contingent consideration
$
95,000

 
$
95,000

 
$

 
$

 
$
95,000


 
December 31, 2018
 
 
 
 
 
Fair Value Measurement Based on
 
Carrying Amount
 
Fair Value
 
Quoted Prices in Active
Markets
(Level 1)
 
Significant other Observable
Inputs
(Level 2)
 
Significant Unobservable
Inputs
(Level 3)
Assets:
 
 
 
 
 
 
 
 
 
Money market funds
(cash equivalents)
$
40,365

 
$
40,365

 
$
40,365

 
$

 
$

Liabilities:
 
 
 
 
 
 
 
 
 
Contingent consideration
$
48,400

 
$
48,400

 
$

 
$

 
$
48,400

Summary of Contingent Consideration Liability
The following table sets forth a summary of the change in the fair value of the Company's contingent consideration liability, measured on a recurring basis at each reporting period, for the nine months ended September 30, 2019 (in thousands):
Balance at December 31, 2018
$
48,400

Change in fair value of contingent consideration
(1,000
)
Balance at March 31, 2019
47,400

Change in fair value of contingent consideration(1)
44,000

Balance at June 30, 2019
91,400

Change in fair value of contingent consideration(2)
3,600

Balance at September 30, 2019
$
95,000


The fair value of the Company’s contingent consideration was determined using probabilities of successful achievement of regulatory milestones and commercial sales, the period in which these milestones and sales are expected to be achieved ranging from 2021 to 2033, the level of commercial sales of Vicinium forecasted for the United States, Europe, Japan and other potential markets, and discount rates ranging from 6.6% to 13.7% as of December 31, 2018 and 5.8% to 12.2% as of September 30, 2019. There have been no changes to the valuation methods utilized during the nine months ended September 30, 2019.
(1) During the quarter ended June 30, 2019, management reassessed the total addressable global market for NMIBC and determined that both the global market size and the estimated potential Vicinium commercial sales within the global market were likely higher than the Company’s previous estimates. Specific drivers of the increased revenue estimates include the expectation that Vicinium could achieve peak market penetration earlier than previously estimated and the expectation that Vicinium sales outside the United States could be two to three times the expected sales volumes in the United States. As contingent consideration incorporates a royalty rate of 2% on all commercial net sales of Vicinium through December 2033, an increase in expected future net sales correlated to a $44.0 million increase in the estimated fair value of the Company’s contingent consideration as of June 30, 2019.
(2) The $3.6 million increase in the estimated fair value of contingent consideration was primarily attributable to a slightly lower discount rate, based on prevailing market conditions as of September 30, 2019, applicable to the earnout royalty payments potentially payable to Viventia's shareholders under the Share Purchase Agreement.